MASI

MASI

USD

Masimo Corporation Common Stock

$163.740+1.500 (0.925%)

Precio en Tiempo Real

Healthcare
Dispositivos médicos
Estados Unidos

Gráfico de Precios

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$162.240

Máximo

$163.890

Mínimo

$161.480

Volumen

0.08M

Fundamentos de la Empresa

Capitalización de Mercado

8.8B

Industria

Dispositivos médicos

País

United States

Estadísticas de Negociación

Volumen Promedio

0.59M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $101.61Actual $163.740Máximo $194.88

Informe de Análisis de IA

Última actualización: 27 abr 2025
Generado por IAFuente de Datos: Yahoo Finance, Bloomberg, SEC

MASI (Masimo Corporation Common Stock): Analyzing Recent Moves & What Might Come Next

Stock Symbol: MASI Generate Date: 2025-04-27 02:22:53

Alright, let's break down what's been going on with Masimo stock based on the latest info we've got. We'll look at the news, the price chart, and what some AI is predicting.

Recent News Buzz: Not Much Shaking Here

The news flow for Masimo lately seems pretty quiet, at least based on what's provided. We saw Needham, an analyst firm, basically stick to their "Hold" rating back on April 10th. Think of a "Hold" rating as saying, "Yeah, things are okay, nothing major screaming buy or sell right now." It's a neutral stance, not really pushing the stock one way or the other.

There was also news about Dexcom, a different company in the healthcare space, appointing a new chief commercial officer. While it's good to know what competitors are up to, this specific piece of news about Dexcom's internal hiring doesn't really tell us much directly about Masimo's business or stock prospects.

So, the takeaway from the news? It's mostly a non-event. No big positive or negative catalysts popping up from these headlines.

Price Check: A Wild Ride, Then a Recent Climb

Looking at the stock's journey over the past few months, it's been quite volatile. After climbing nicely through January and February, hitting a peak around the $190 mark in late February, things took a turn. The price dropped significantly in March and then saw a really sharp plunge in early April, dipping down into the low $140s and even high $130s around April 7th.

Since that early April low point, the stock has been working its way back up. The last few trading days in April show a clear upward push, moving from the low $150s towards the mid-$160s. The last recorded price was $163.74 as of April 25th.

So, the recent trend is definitely positive, showing some recovery and momentum after that earlier steep fall.

Now, what about the AI's crystal ball? The prediction model suggests the stock might stay flat today (0.00% change), then see a small dip tomorrow (-0.26%), followed by a slightly larger dip the day after (-1.73%). This contrasts a bit with the recent upward price action we just saw.

Putting It Together: What Does This Mean?

Okay, let's connect the dots. We have neutral news, a recent price chart showing good upward momentum after a big drop, and an AI prediction that calls for a slight pullback soon.

This creates a bit of a mixed picture. The recent price strength and the bullish technical signals mentioned in the recommendation data (like the MACD Golden Cross and strong volume on some days) suggest there's buying interest right now. However, the AI prediction hints that this recent bounce might face some near-term selling pressure. Also, it's worth noting the company's fundamentals, like revenue growth and return on equity, aren't looking super strong according to the recommendation data, and debt is relatively high.

Given the recent upward move but the AI's forecast for a dip, the situation isn't a screaming "buy everything now" or "sell everything immediately." It might lean towards a "watch and wait" approach, or perhaps looking for potential entry points if the predicted dip occurs.

  • Potential Strategy Idea (Cautious): If you're thinking about getting in, and you trust the AI's short-term prediction, you might consider waiting to see if the stock pulls back a bit towards the lower end of the recent trading range or the recommended entry levels (around $162-$163). Waiting for a dip could offer a better price if the AI is right.
  • Managing Risk: For anyone holding or considering a position, setting a stop-loss is always smart. The recommendation data suggests a potential stop-loss level around $153.58. This level is below the recent consolidation area before the latest surge, so a drop below it might signal the recent momentum is fading.
  • Potential Upside Target: The recommendation data also points to a potential take-profit level around $167.03. This is close to recent highs and could be a point to consider if the upward trend continues briefly.

Remember, these are just potential ideas based on the data points we have. The market can do anything.

Company Context: What Masimo Does

Just a quick reminder about Masimo itself: They're a healthcare technology company, big in patient monitoring devices (like pulse oximeters) and hospital automation. Their business is tied to the healthcare sector. The company has a market cap of around $8.8 billion, and its PE ratio is around 35x, which the recommendation data calls "neutral." It's had a wide trading range over the past year, from about $101 to $194. Knowing they are in medical devices helps understand why things like hospital spending or new device approvals can impact them.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Noticias Relacionadas

Analyst Upgrades

Needham Reiterates Hold on Masimoto Hold

Needham analyst Mike Matson reiterates Masimo from Hold to Hold.

Ver más
Needham Reiterates Hold on Masimoto Hold
BusinessWire

Dexcom Appoints Jon Coleman as Chief Commercial Officer

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global

Ver más
Dexcom Appoints Jon Coleman as Chief Commercial Officer

Predicción de IABeta

Recomendación de IA

Bajista

Actualizado el: 27 abr 2025, 21:23

BajistaNeutralAlcista

64.0% Confianza

Riesgo y Negociación

Nivel de Riesgo3/5
Riesgo Medio
Adecuado Para
Moderado
Guía de Negociación

Punto de Entrada

$162.29

Toma de Ganancias

$167.03

Stop Loss

$153.58

Factores Clave

PDI 9.5 está por encima de MDI 5.4 con ADX 11.4, lo que sugiere una tendencia alcista
El precio actual está extremadamente cerca del nivel de soporte ($163.05), lo que sugiere una fuerte oportunidad de compra
El volumen de operaciones es 8.2 veces el promedio (6,726), lo que indica una presión de compra extremadamente fuerte
El MACD 0.1870 está por encima de la línea de señal 0.1410, lo que indica un cruce alcista

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.